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Abstract
Background: Central pancreatectomy has a unique application for lesions in the neck of the
pancreas. It preserves the distal pancreas and its endocrine functions. It also preserves the spleen.
Methods: This is a retrospective review of 10 patients who underwent central pancreatectomy
without pancreatico-enteric anastomosis between October 2005 and May 2009. The surgical
indications, operative outcomes, and pathologic findings were analyzed.
Results: All 10 lesions were in the neck of the pancreas and included: 2 branch intraductal papillary
mucinous neoplasms (IPMNs), a mucinous cyst, a lymphoid cyst, 5 neuroendocrine tumors, and a
clear cell adenoma.
Conclusion: Central pancreatectomy without pancreatico-enteric anastomosis for lesions in the
neck and proximal pancreas is a safe and effective procedure. Morbidity is low because there is no
anastomosis. Long term endocrine and exocrine function has been maintained.
Introduction
In 1957, Guillemin and Bessot [1] described central pan-
createctomy (CP) in a patient with chronic pancreatitis.
Central pancreatectomy (CP) has since been used in select
cases for treating pancreatitis, most often for benign and
low grade malignant lesions in the neck of the pancreas
[2-4]. Potential advantages of central pancreatectomy
include preservation of endocrine, exocrine, and splenic
function [3,5-7].
Benign or low-grade malignant lesions in the neck of the
pancreas have been treated surgically, either by pancreati-
Published: 31 August 2009
World Journal of Surgical Oncology 2009, 7:67 doi:10.1186/1477-7819-7-67
Received: 1 July 2009
Accepted: 31 August 2009
This article is available from: http://www.wjso.com/content/7/1/67
© 2009 Wayne et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.World Journal of Surgical Oncology 2009, 7:67 http://www.wjso.com/content/7/1/67
Page 2 of 5
(page number not for citation purposes)
coduodenectomy resection (PDR) or distal pancreatec-
tomy with splenectomy (DPS) or splenic preserving distal
pancreatectomy (SPDP). Each operation involves a resec-
tion of a major portion of the pancreas, which in a dis-
eased pancreas can worsen diabetes mellitus and/or
exocrine insufficiency [8,9]. This paper will discuss the
technique and benefits of a resection of the central por-
tion of the pancreas; a simplification of the procedure,
and a literature review of the topic.
Materials and methods
A review of patients who underwent CP between October
2005 and May 2009 at St. Vincent's Medical Center was
done after approval by the Institutional Review Board.
The mean age of patients was 54 ± 15 years and ranged
from 34 to 77 years old. There were 5 male and 5 female
patients in the study. Each patient in the study was asymp-
tomatic and the lesions were discovered incidentally by
CT scan, which was done for other reasons. Each patient
was then evaluated by CT angiography and endoscopic
studies, which included ERCP, EUS, biopsy, and cytology.
(Table 1)
Technical aspects
Each operation was performed through an upper midline
incision. The stomach is retracted downwards while the
gastro-hepatic omentum is incised exposing the neck,
body, and a portion of the tail of the pancreas. The gastro-
colic omentum is dissected as needed. If necessary, the
stomach can be retracted superiorly while the transverse
colon is retracted downwards and this facilitates exposure
of the lower border of the pancreas and dissection of the
superior mesenteric vein (SMV) behind the pancreas. Stay
sutures are placed on either side of the lesion in the supe-
rior and inferior aspect of the pancreas. This facilitates dis-
section from the SMV and the stay sutures also help to
control the transverse pancreatic vessels as well. Once the
SMV is completely dissected from the pancreas, the distal
margin of pancreas is transected, while protecting the
SMV. The specimen is then excised by transecting the
proximal margin. (Figure 1) The lesion is then sent to
pathology to be evaluated for margins by frozen section,
an example is seen in figure 2. The transected pancreas is
oversown after ligating both ends of the transected pan-
creatic duct. The pancreatic duct is suture ligated with a 4-
0 vicryl suture and then the transected pancreas is over-
sewn with a running 4-0 prolene suture, imbricating the
pancreatic capsule. A drain is placed and the abdomen is
closed in standard fashion. The drains were removed
upon discharge because there were no fistulas in our
group.
Results
The resected lesions included a branch IPMN in 2
patients, a mucinous cyst, a lymphoid cyst, five neuroen-
docrine tumors, and a clear cell adenoma (Table 1). The
mean operative time was 73.5 ± 10 minutes, and the esti-
mated blood loss was 164 ± 89 ml. There were no mortal-
ities in the study. The postoperative length of stay (LOS)
was 5.9 ± 9.5 days (range 4 to 30); however, this was
Table 1: Patient summary
Patient Gender Age Pathology PMHx Complications
1 M 77 IPMT CAD, COPD Pneumonia
2 F 68 IPMT DM, HTN, obesity Local wound infection
3 F 71 Mucinous cystic neoplasm HTN None
4 M 57 Lymphoid cystic neoplasm COPD, obesity Local wound infection
5 F 34 Neuroendocrine tumor None None
6 M 66 Neuroendocrine tumor None Local wound seroma
7 F 46 Clear cell adenoma None None
8 F 49 Neuroendocrine tumor None None
9 M 43 Neuroendocrine
Tumor
Obesity None
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skewed by one patient with COPD, who had pneumonia
postoperatively and was hospitalized for 30 days. The LOS
for the other patients in the study was 4.8 ± 0.75 days.
Other postoperative complications included a superficial
wound infection in 2 patients, and a wound seroma in
one patient. These three patients were also obese.
Discussion
Central pancreatectomy has a unique application in cer-
tain patients with focal, chronic pancreatitis and trauma.
It is utilized mostly for benign and low-grade malignant
lesions in the neck of the pancreas [5,9-12]. The potential
benefit of CP is to preserve pancreatic function and the
spleen by limiting resection of normal parenchyma [2].
Diabetes mellitus (DM) occurs in 20% of patients follow-
ing distal pancreatectomy [13-15]. Endocrine insuffi-
ciency is more frequent in patients with chronic
pancreatitis and approaches 50% within 5 years after dis-
tal pancreatectomy (DP). Endocrine and exocrine insuffi-
ciency depends on residual function of the pancreas and
the severity of pancreatitis [16]. The long-term risk of DM
after pancreatic resection is greater after distal resection of
the pancreas rather than after CP (11%, vs 50%) [8], par-
ticularly in an already diseased gland. The benefits of CP
are obvious regarding pancreatic and splenic function
[3,6,17]. Preservation of splenic function in the pediatric
population may be important. Most CPs have utilized a
pancreatico-jejunal or pancreatico-gastric anastomosis to
the distal pancreas. The incidence of postoperative fistula
in patients with a CP anastomosis ranges from 8% to 40%
with a re-operative rate as high as 12% [2,9,18-20]. The
incidence of a pancreatic leak after CP and pancreatic
anastomosis is summarized in Table 2.
We suspect the relative frequency of a pancreatic fistula
after CP is due to a small pancreatic duct and a normal soft
distal gland. These two factors (a small duct and soft
parenchyma) account for a higher fistula rate after pancre-
atico-duodenal resection (PDR). This is our reasoning for
omitting a pancreatico-enteric anastomosis during CP. In
our experience, the distal pancreatic tissue is usually nor-
mal and the duct is small in diameter. The indications for
CP in chronic pancreatitis are few since focal pancreatitis
confined to the neck of gland is unusual. CP may be tech-
nically more difficult because of chronic inflammation in
these patients [2]. Furthermore, in patients with a pancre-
aticogastrostomy, fistula rates aside, exocrine function
may not be preserved. Pancreatic enzymes, particularly
lipase, are inactivated in an acidic environment [21-23].
Our series of 10 patients supports the value of resection
without anastomosis in a short follow up period. To date,
none of the patients in the study have developed any
endocrine or exocrine deficiencies. So far, the morbidity
of a pancreatic leak is removed while exocrine function is
Operative site after removal of central portion of the pan- creas Figure 1
Operative site after removal of central portion of the 
pancreas.
Proximal
pancreas Splenic vein 
Distal pancreas 
Gross section of the tumor, diameter 2.8 cm Figure 2
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preserved in the head and neck and endocrine function
remains in both segments of pancreas when using central
pancreatectomy without an anastomosis.
Conclusion
CP without an anastomosis may reduce the morbidity and
length of hospital stay compared to patients undergoing
CP with an anastomosis. It has been shown to be a safe,
effective procedure which does not compromise pancre-
atic function.
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